Photo of Deniz Can Guven/X
May 18, 2024, 06:04
Deniz Can Guven: The 1st-in-human phase 1 study on arginase inhibitor INCB001158
Deniz Can Guven, Medical Oncologist at , shared on X/Twitter:
”The 1st-in-human phase 1 study on arginase inhibitor INCB001158 is out on BMJ Oncology.
Led by my great mentor Aung Naing.
Tested a strong preclinical hypothesis:
- A total of 107 patients.
- Monotherapy or with pembrolizumab.
- + Tolerable with fatigue and GI adverse events.
- – Very limited efficacy.
Need more data on the role of arginine metabolism in TME immunosuppression. Kudos to all authors.”
Read further.
Source: Deniz Can Guven/X
Aung Naing
BMJ Oncology
cancer
Deniz Can Guven
Elena Garralda
Emil Kuriakose
Glenn J. Hanna
Health Sciences University
Howard Kallender
immunotherapy
Kyriakos P Papadopoulos
LuLu Cheng
Michael J Pishvaian
Michael Smith
Mike Pishvaian
Omar Saavedra
OncoDaily
Oncology
Osama Rahma
pembrolizumab
Sven Gogov
TME immunosuppression
Todd Bauer
Xuejun Chen
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 13:44
Nov 14, 2024, 13:37
Nov 14, 2024, 13:32
Nov 14, 2024, 13:29
Nov 14, 2024, 13:02
Nov 14, 2024, 12:44